India’s Opportunity to Lead the Shift to Non-Animal Drug Testing

Syllabus: GS3/ Biotechnology, GS4/ Ethics

Context

• The Non-Animal Testing Models (NAMs) are emerging as scientifically credible alternatives and complements to the traditional animal testing, presenting an opportunity for India to further strengthen its pharmaceutical innovation ecosystem.

What are Non-Animal Testing Models (NAMs)? 

• Non-animal testing methods (NAMs) are scientific approaches that use human-relevant biological systems and computational methods to generate safety, efficacy and toxicity information, instead of relying solely on animal testing.
• Types of NAM platforms are as;
  • Organoids: Miniature three-dimensional structures grown from human stem cells that mimic the architecture and function of human organs.
  • Organ-on-chip systems: Microfluidic devices that recreate the physiological environment of human tissues and organ interactions.
  • Three-dimensional human cell culture models: Advanced cellular systems that better replicate human tissue behaviour than conventional two-dimensional cultures.
  • Computational toxicology: Computer-based models that predict chemical toxicity and drug responses using biological and chemical data.
  • Artificial Intelligence (AI)-enabled models: Machine learning systems that analyse large biomedical datasets to predict human drug responses.

Why is a Shift Needed?

• Limitations of conventional animal testing: Animal physiology, metabolism, immune responses and disease mechanisms differ from those of humans, so traditional animal models often do not accurately predict human biological responses.
• Drug development challenge: Globally, only about 10–14% of drug candidates entering Phase I clinical trials ultimately receive regulatory approval.
  • A major reason is the inability of some preclinical models to reliably predict human safety and efficacy outcomes.
• Ethical Considerations: These models reduce or eliminate the need for live animals (such as rodents and primates) in painful or fatal testing procedures.
• India’s Existing Strengths: India possesses a robust generic pharmaceutical industry, enabling it to emerge as a major global supplier of affordable medicines.
  • However, future growth in the pharmaceutical sector will increasingly depend on innovation-driven value creation rather than only large-scale manufacturing.

Global Trends in NAM Adoption

• The United States has passed the FDA Modernization Act 2.0 officially ending the decades-old federal mandate that required animal testing for all new drug applications.
• The European Union: The EU has a deeply integrated approach to safety testing under the REACH framework.
  • The European Commission and the European Chemicals Agency (ECHA) adopted a comprehensive roadmap to completely phase out animal testing for chemical safety assessments.
• The United Kingdom has created national centres and research networks focused on human-relevant testing technologies and the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) is the primary organization leading this.
• Japan: Japan has invested in toxicology infrastructure through the Japanese Center for the Validation of Alternative Methods (JaCVAM)

Evolution of NAM Use in India

• The Department of Biotechnology has undertaken initiatives to nurture and develop 3D tissue models like organoid models or in-vitro systems- 3D printed models for potential applications in cell therapy, pre-clinical models for drug discovery, in-vitro cell based models for understanding disease pathophysiology.
• Platforms such as Caenorhabditis elegans (C. elegans), Drosophila melanogaster, zebrafish systems, and yeast-based models have been adopted for toxicology, disease modelling and drug screening.
• India recognised Non-Animal Testing Models (NAMs) in the drug-development pipeline by amending the New Drugs and Clinical Trials Rules, 2019 in 2023.

Opportunities for India

• Strengthen intellectual property creation: Advanced testing platforms support original drug discovery, novel biologics and proprietary technologies, thereby helping India generate stronger patents and innovation-based intellectual property.
• India’s global competitiveness: Early adoption of human-relevant testing technologies can attract international collaborations, investment and high-value research projects, positioning India as a global hub for drug discovery and biomedical innovation.

Way Ahead

• India should integrate NAMs into generic drug quality assessment and biosimilar development through a phased approach that does not disrupt existing manufacturing systems.
• India should establish a national regulatory framework for NAMs, with clear validation protocols, data acceptance guidelines and coordination among regulatory agencies, industry and research institutions.
• Early adoption of NAMs will position India as a preferred destination for innovative drug discovery, translational research and next-generation pharmaceutical development.

Source: TH